What Cogent Biosciences, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 2 | 8 |
| Total trades | 4 | 31 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 45,510 | 9,884,510 |
| Disposed | 45,510 | 12,047,772 |
| Net activity | +0 | −2,163,262 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Morris Arlene | Director | Aug 27 | Open-market sale · S | −3,161 | $37.54 | −$119K | 0 |
| Morris Arlene | Director | Aug 27 | Open-market sale · S | −42,349 | $37.09 | −$1.57M | 3,161 |
| Morris Arlene | Director | Aug 27 | Exercise / conversion · M | +3,583 | $2.52 | +$9.03K | 45,510 |
| Morris Arlene | Director | Aug 27 | Exercise / conversion · M | +41,927 | $5.64 | +$236K | 41,927 |
| Robbins Andrews R | President and CEO | May 19 | Gift · G | +160,000 | — | — | 160,000 |
| Robbins Andrews R | President and CEO | May 19 | Gift · G | −160,000 | — | — | 497,503 |
| Fairmount Funds Management Llc | Director | Mar 31 | Open-market sale · S | −7,000,000 | $34.66 | −$243M | 5,503,418 |
| Fairmount Funds Management Llc | Director | Mar 31 | Derivative Conversion · C | +7,000,000 | — | — | 12,503,418 |
| Fairmount Funds Management Llc | Director | Jan 22 | Open-market sale · S | −3,500,000 | $36.40 | −$127M | 5,503,418 |
| Green John L. | Chief Financial Officer | Dec 26 | Open-market sale · S | −77,000 | $38.68 | −$2.98M | 131,834 |
| Robinson John Edward | Chief Scientific Officer | Dec 26 | Open-market sale · S | −90,000 | $38.74 | −$3.49M | 140,002 |
| Sachs Jessica | Chief Medical Officer | Dec 26 | Open-market sale · S | −82,642 | $38.70 | −$3.2M | 133,938 |
| Kearns Evan | Chief Legal Officer | Dec 26 | Open-market sale · S | −65,000 | $38.70 | −$2.52M | 109,398 |
| Robbins Andrews R | President and CEO | Dec 17 | Withheld — tax / exercise cost · F | −367,497 | $39.45 | −$14.5M | 657,503 |
| Robbins Andrews R | President and CEO | Dec 17 | Grant / award · A | +840,000 | — | — | 1,025,000 |
| Robbins Andrews R | President and CEO | Dec 17 | Grant / award · A | +185,000 | — | — | 185,000 |
| Green John L. | Chief Financial Officer | Dec 17 | Withheld — tax / exercise cost · F | −145,007 | $39.45 | −$5.72M | 208,834 |
| Green John L. | Chief Financial Officer | Dec 17 | Grant / award · A | +300,000 | — | — | 353,841 |
| Green John L. | Chief Financial Officer | Dec 17 | Grant / award · A | +50,000 | — | — | 53,841 |
| Sachs Jessica | Chief Medical Officer | Dec 17 | Withheld — tax / exercise cost · F | −154,716 | $39.45 | −$6.1M | 216,580 |
Loading...
